Takeda's Oveporexton Phase 3 Data for Narcolepsy Type 1 Published in New England Journal of Medicine

Takeda has announced the publication of results from two Phase 3 studies in the New England Journal of Medicine, evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, for people with narcolepsy type 1 (NT1). Oveporexton is noted as the first and only medicine to address the underlying cause of NT1.